Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
about
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged swordTherapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.Targeting the ATR-CHK1 Axis in Cancer TherapyThe cell cycle checkpoint inhibitors in the treatment of leukemias.TUSC3 induces autophagy in human non-small cell lung cancer cells through Wnt/β-catenin signalingNovel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.ATR/CHK1 inhibitors and cancer therapy.Directing the use of DDR kinase inhibitors in cancer treatment.Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.Targeted DNA sequencing of non-small cell lung cancer identifies mutations associated with brain metastases.Advances in therapeutic targeting of the DNA damage response in cancer.Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors
P2860
Q28078268-22987253-AFAB-4D63-B860-ACE511E71B30Q38660811-DBB9E400-54D7-440E-B5CE-5A26EA9776BDQ38817102-A91F29D5-00C2-4850-BAEF-C3990F90BDE8Q38868502-59FB1251-DA01-424B-B671-A5D0421F4305Q41592988-354FA8CF-334F-412C-A2BF-5FFCD5B6A7C0Q45790068-98682C31-242E-4AB2-88A5-5DEBC640B246Q47130816-72554EA6-EBF5-45F6-AE89-91550BA60EF0Q47622968-D516AD9D-5E15-4BB9-89FA-51AEC3DDE54EQ47687840-5C778070-7742-4F69-B08A-2EF3696595EDQ54116465-F0B2172B-47B5-486F-AE77-5B34E6941B30Q55117380-FEF992DE-B814-4FFE-87AB-CB08239311E5Q55306606-55BE159C-671A-46CE-B383-C74614BA4D37Q58701948-48BA8E1E-CE15-4763-BE35-4FAD78DCAB1D
P2860
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Phase II evaluation of LY26036 ...... ic non-small cell lung cancer.
@en
Phase II evaluation of LY26036 ...... ic non-small cell lung cancer.
@nl
type
label
Phase II evaluation of LY26036 ...... ic non-small cell lung cancer.
@en
Phase II evaluation of LY26036 ...... ic non-small cell lung cancer.
@nl
prefLabel
Phase II evaluation of LY26036 ...... ic non-small cell lung cancer.
@en
Phase II evaluation of LY26036 ...... ic non-small cell lung cancer.
@nl
P2093
P2860
P1476
Phase II evaluation of LY26036 ...... tic non-small cell lung cancer
@en
P2093
Aimee Bence Lin
David Smith
Donald A Richards
Emily Nash Smyth
Jin Hyoung Kang
Keunchil Park
Mary Pinder-Schenck
Richard Rosenberg
Sameera Wijayawardana
P2860
P2888
P304
P356
10.1007/S10637-016-0368-1
P577
2016-06-27T00:00:00Z